Dyne Therapeutics Inc

The proposal asks shareholders to approve, on a non-binding advisory basis, the compensation disclosed for named executive officers (NEOs). Management seeks approval to validate executive pay practices that combine base salary, annual performance-based cash bonuses tied to corporate goals, and equity incentives including stock options and RSUs with service and market-based vesting conditions. The company cites 2025 clinical and financing milestones and a 95% corporate performance score used to determine bonuses; management views its pay design as aligned with long-term stockholder value and retention. The board recommends a 'FOR' vote, arguing that compensation practices are market-competitive, include clawback and anti-hedging policies, and use independent compensation consultants and peer benchmarking to mitigate excessive risk-taking. Because the vote is advisory, it does not bind the board, but the compensation committee will consider stockholder feedback for future decisions. The proposal reflects typical 'say-on-pay' considerations in corporate governance and arises in the context of significant clinical progress, equity grants with market-based vesting tied to stock performance, and substantial capital raises during 2025.

Management requests shareholder approval to amend the charter to double authorized common shares to 400 million (and total authorized to 410 million including preferred), citing operational flexibility to support financings, equity incentive plans, potential strategic transactions and other corporate needs without the delay and cost of seeking shareholder approval in the future. The board emphasizes that substantial issuance is anticipated for equity compensation, the at-the-market offering, and potential future capital raises given the company’s cash runway goals and $1.1 billion in cash as of year-end. Management notes there are currently only ~5.9 million unreserved shares available, which could constrain future financing options. While dilution concerns exist, the board argues the amendment is prudent to preserve financial agility, and contends that the increase could deter hostile takeovers but is primarily for legitimate operational flexibility. The board recommends a 'FOR' vote and frames the amendment as necessary to support growth, capital strategy, and employee compensation while cautioning that future issuances could dilute existing shareholders and affect share price.

This management proposal seeks shareholder approval to amend the charter to extend limited monetary liability protection—already afforded to directors—to certain officers to the fullest extent permitted by the DGCL. Management’s stated rationale is recruitment and retention of senior executives in a competitive market and to harmonize officers’ protections with those of directors, thereby mitigating litigation risks from hindsight-based claims and discouraging plaintiffs’ counsel from adding officers to suits after director claims are dismissed. The amendment expressly excludes exculpation for claims brought by the company, derivative claims, breaches of loyalty, acts not in good faith, intentional misconduct, knowing violations of law, and transactions where improper personal benefit is alleged, limiting its protective scope. The board argues that the change is narrowly tailored, consistent with many peers, and would not impair stockholder remedies for derivative actions or other serious misconduct, while potentially reducing frivolous litigation and improving officer recruitment. Shareholders should weigh the recruitment/retention benefits and reduced litigation costs versus concerns that expanded exculpation could reduce officer accountability or shift litigation consequences. The board recommends a 'FOR' vote.